Free tool
FAERS Monitor: Fanapt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022192 or its brand name (Fanapt, Iloperidone). Reports on generic versions are filed under their own applications.
Reports
1,476
Serious
722
49% of reports
Hospitalization
222
Death reported
60
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective108
- dizziness107
- insomnia83
- weight increased83
- anxiety70
- fatigue68
- nausea54
- dyskinesia51
- suicidal ideation49
- dyspnoea48
- off label use48
- somnolence48
- aggression45
- tachycardia43
- vomiting43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 75 |
| 2011 | 134 |
| 2012 | 393 |
| 2013 | 76 |
| 2014 | 84 |
| 2015 | 64 |
| 2016 | 60 |
| 2017 | 82 |
| 2018 | 76 |
| 2019 | 87 |
| 2020 | 46 |
| 2021 | 49 |
| 2022 | 34 |
| 2023 | 27 |
| 2024 | 28 |
| 2025 | 73 |
| 2026 | 87 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,683 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyskinesiaSignal | 51 | 17.9 | 13.7 | 798 |
| aggressionSignal | 45 | 12.8 | 9.6 | 480 |
| suicidal ideationSignal | 49 | 7.6 | 5.8 | 277 |
| tachycardiaSignal | 43 | 6.9 | 5.1 | 212 |
| weight increasedSignal | 83 | 5.3 | 4.3 | 287 |
| insomniaSignal | 83 | 4.4 | 3.6 | 221 |
| anxietySignal | 70 | 3.5 | 2.8 | 125 |
| somnolenceSignal | 48 | 3.4 | 2.6 | 80 |
| dizzinessSignal | 107 | 3.1 | 2.5 | 150 |
| vomiting | 43 | 1.3 | 1.0 | 3 |
| fatigue | 68 | 1.2 | 1.0 | 3 |
| dyspnoea | 48 | 1.2 | 0.9 | 2 |
| drug ineffective | 108 | 1.2 | 1.0 | 3 |
| nausea | 54 | 1.0 | 0.7 | 0 |
| off label use | 48 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.